

# John Markman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/620619/publications.pdf>

Version: 2024-02-01

20  
papers

568  
citations

840585

11  
h-index

794469

19  
g-index

21  
all docs

21  
docs citations

21  
times ranked

939  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multimethod quantitative benefitâ€risk assessment of treatments for moderateâ€toâ€severe osteoarthritis. British Journal of Clinical Pharmacology, 2022, , .	1.1	4
2	Systematic Review of Research Methods and Reporting Quality of Randomized Clinical Trials of Spinal Cord Stimulation for Pain. Journal of Pain, 2021, 22, 127-142.	0.7	9
3	Research design considerations for randomized controlled trials of spinal cord stimulation for pain: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials/Institute of Neuromodulation/International Neuromodulation Society recommendations. Pain, 2021, 162, 1935-1956.	2.0	38
4	Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlledâ€Japaneseâ€Phase IIIâ€safety study. Pain Management, 2021, , .	0.7	3
5	Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS). Pain Medicine, 2020, 21, 1347-1356.	0.9	7
6	Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety. Pain, 2020, 161, 2068-2078.	2.0	34
7	AAPT Diagnostic Criteria for Chronic Low Back Pain. Journal of Pain, 2020, 21, 1138-1148.	0.7	14
8	SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain. Pain, 2019, 160, 1374-1382.	2.0	18
9	Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone. Journal of Pain Research, 2018, Volume 11, 2051-2059.	0.8	5
10	Efficacy of pregabalin in post-traumatic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Neurology, 2018, 265, 2815-2824.	1.8	18
11	Why are there no drugs indicated for sciatica, the most common chronic neuropathic syndrome of all?. Drug Discovery Today, 2018, 23, 1904-1909.	3.2	8
12	Using Random Forest Models to Identify Correlates of a Diabetic Peripheral Neuropathy Diagnosis from Electronic Health Record Data. Pain Medicine, 2017, 18, 107-115.	0.9	41
13	Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. Postgraduate Medicine, 2017, 129, 102-110.	0.9	22
14	Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallelâ€Group, Randomized, Placeboâ€controlled Clinical Trials. Pain Practice, 2017, 17, 718-728.	0.9	19
15	Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy. Journal of Diabetes and Its Complications, 2015, 29, 212-217.	1.2	91
16	Spanish Translation and Linguistic Validation of the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R). Pain Medicine, 2014, 15, 876-877.	0.9	1
17	Spinal pain. Neurology: Clinical Practice, 2014, 4, 277-279.	0.8	0
18	The ACTION-American Pain Society Pain Taxonomy (AAPT): An Evidence-Based and Multidimensional Approach to Classifying Chronic Pain Conditions. Journal of Pain, 2014, 15, 241-249.	0.7	159

#	ARTICLE	IF	CITATIONS
19	Considerations for extrapolating evidence of acute and chronic pain analgesic efficacy. <i>Pain</i> , 2011, 152, 1705-1708.	2.0	36
20	Lumbar Spinal Stenosis in Older Adults: Current Understanding and Future Directions. <i>Clinics in Geriatric Medicine</i> , 2008, 24, 369-388.	1.0	41